About 75% of the EOC tumors expressed both, one of the tumor antigens and MHC class I. This observation underlines the relevance of designing a multiepitope vaccine consisting of p53, SP17, NY-ESO-1, survivin, and WT1 for the immunotherapeutic treatment of ovarian cancer. This evidence concerns the gene BIRC5 and neoplasm.